UnitedHealthcare to Remove Prior Authorization for Many Services by 2026

Understanding 'Ghost Fat': A New Phenomenon from Weight-Loss Injections

Individuals who have used injectable weight-loss medications are reporting a phenomenon known as 'ghost fat.' This term refers to the lingering behaviors and habits that persist even after significant weight loss, as users may subconsciously continue actions associated with their previous larger size. This psychological effect can impact their ongoing weight management and self-image. Understanding 'ghost fat' is crucial for both users and healthcare providers to address potential challenges in maintaining a healthy lifestyle post-treatment.

Understanding 'Ghost Fat': A New Phenomenon from Weight-Loss Injections

Recent findings reveal that individuals using injectable weight-loss medications may experience a phenomenon known as 'ghost fat.' This term refers to the lingering psychological effects and behaviors that persist even after significant weight loss. As people shed pounds, they might unconsciously maintain habits associated with their previous larger size, impacting their mental health and body image. This issue highlights the importance of addressing both physical and psychological aspects of weight loss treatments. Awareness of 'ghost fat' can help those affected navigate their post-weight-loss journey more effectively.

Uncertainty Surrounds FDA Decision on Moderna's mRNA Flu Vaccine for Seniors

An FDA advisory panel has recommended the use of Moderna's mRNA flu vaccine for older adults, but the absence of a permanent vaccine chief and commissioner raises questions about the decision-making process. This recommendation is significant as it could enhance flu prevention among vulnerable populations, particularly seniors who are at higher risk for severe illness. The timeline for a final decision remains unclear, leaving many in the healthcare community and potential vaccine recipients in anticipation of the next steps.

Uncertainty Surrounds Final Decision on Moderna's mRNA Flu Vaccine for Seniors

An FDA advisory panel has recommended the use of Moderna's mRNA flu vaccine specifically for older adults. However, the decision-making process is complicated by the absence of a permanent vaccine chief and commissioner at the FDA, leaving uncertainty about who will ultimately approve the vaccine. This recommendation is significant as it could enhance flu protection for seniors, a demographic particularly vulnerable to severe illness. The timeline for a final decision remains unclear, impacting both public health strategies and vaccine availability for the upcoming flu season.